AYTU BIOPHARMA, INC — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Joshua R. Disbrow (CEO) and Ryan J. Selhorn (CFO) certified on November 16, 2026 that the Q3 2026 10-Q for the quarter ended September 30, 2026 complies with SEC requirements, contains no material untrue statements, and fairly presents financial condition and results of operations. Standard Sarbanes-Oxley Sections 302 and 906 certifications with no disclosed control weaknesses or fraud.
Why this rating
Routine SOX certification exhibits; no substantive business disclosures present in excerpt. Standard periodic compliance filing.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.